Delta-Fly Pharma (4598) · PolicyRestated
Managing the business based on pipeline-related revenue rather than ROA or ROE
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2026.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Managing Corporate Goals Through R&D Pipeline ProgressA theme 7 companies write about · 0 as a headwind · 6 as a tailwind
5 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2026RestatedAnnual report
「Accordingly, rather than setting management indicators such as ROA and ROE as targets, we conduct our business with revenue generated in line with progress in the development pipeline as our target.」
ROA・ROEではなく、開発パイプラインの進捗に応じた収入を目標とする経営管理方針を再確認している。 - FY2024First statedAnnual report
「Accordingly, rather than setting management indicators such as ROA and ROE as targets, we conduct our business with revenue generated in line with progress in the development pipeline as our target.」
ROAやROEを目標とせず、開発パイプラインの進捗に応じた収入を経営上の目標とする考え方が、目標とする経営指標の節で初めて独立して示された。